Background: Recombinant factor VIIa (rFVIIa) is approved for treatment of bleeding in patients who have hemophilia with inhibitors but has been applied to a wide range of off-label indications.
T
o be approved by the U.S. Food and Drug Administration (FDA), medications must clear many regulatory hurdles and demonstrate both efficacy and a lack of excessive harms in clinical trials. After a medication has received approval, there are no further limitations on its use, either on-or off-label. In many cases, this leads to medications being approved for narrowly defined indications, followed by substantial use in areas that have not been well-studied (1) .
The FDA approved recombinant factor VIIa (rFVIIa) (Novo Nordisk, Bagsvaerd, Denmark) in 1999 for treatment of spontaneous or surgical bleeding episodes in patients with hemophilia A or B who have inhibitors to factor VIII or factor IX. When first introduced, rFVIIa was used predominantly for these indications. After it became widely available, however, rFVIIa was rapidly used in the treatment or prophylaxis of bleeding in other conditions. Although rFVIIa activity is thought to be confined to sites of endothelial injury (2, 3) , the potential for thromboembolic complications with its use has been demonstrated in several trials and retrospective analyses (4 -9), raising concern about potential harms with widespread, offlabel application. To estimate patterns of off-label, inhospital use of rFVIIa, we performed a retrospective evaluation of data from the Premier Perspectives database (Premier, Charlotte, North Carolina) of U.S. hospitals. This representative sample was used to project national usage patterns from 1 January 2000 to 31 December 2008.
METHODS

Design
We purchased access to data from the Premier Perspectives database. The data set encompassed all hospitalizations during which rFVIIa was ordered for a patient from 1 January 2000 to 31 December 2008. We analyzed this data set to categorize the discharge diagnoses and patient outcome for each rFVIIa-associated hospitalization.
Hospital Sample
The Premier Perspectives database contains data from 615 nonfederal U.S. hospitals. Institutional participation in the database is voluntary. Data included are patient demographic characteristics; primary and secondary diagnoses (coded by International Classification of Diseases, Ninth Revision ); length of hospital stay; medications used; and disposition for each hospitalization. We identified 12 644 hospitalizations in which rFVIIa was administered to patients from 2000 to 2008. A total of 286 100 ICD-9 diagnosis and procedure codes were reported for this cohort.
Categorizations of Use
We constructed a descending hierarchy of ICD-9 codes to categorize each case into mutually exclusive indication categories (Appendix Table 1 , available at www .annals.org). This hierarchy started with the most relevant, most reliable, and most specific clinical diagnoses, followed by successively less relevant, less reliable, or less specific diagnoses. A case was assigned to a diagnostic category on the basis of the ICD-9 code that placed it in the highest category in the hierarchy.
The higher-order diagnoses in this hierarchy were the FDA-approved indications of hemophilia A and B, followed by unapproved indications similar to hemophilia or approved in other countries (for example, Glanzmann thrombasthenia). If these diagnoses were noted, the hospitalization was classified into that category regardless of whether other potential indications were also noted. All remaining hospitalizations were then categorized successively for an array of off-label indications (Appendix Table  1 ). Sensitivity analyses of this coding hierarchy had little effect on the main findings. The greatest change in the distribution between indications was seen when trauma was moved lower in the hierarchy, which suggests that trauma frequently occurs in the setting of other disease processes. We chose to prioritize trauma as the indication for treatment in these instances because it was likely trauma and not the associated diagnoses that instigated the use of rFVIIa.
The hematologic conditions not associated with hemophilia were divided into 2 groups. We gave high priority to primary clotting disorders that represent distinct and usually isolated defects in the clotting process. We gave lower priority to secondary clotting disorders that are more likely to be the end product of other pathologic conditions, as with traumatic bleeding causing consumptive coagulopathy or the disruption of clotting produced by liver disease.
Projections
Statistical weights associated with each hospital by quarter were applied for projection of estimated rFVIIa use at the national level. Hospitals providing data to the database represent a convenience sample and may differ from hospitals nationwide; however, the Premier Perspectives database is the largest hospital-based, service-level comparative database in the country. Statistical weighting allows national projections to be made under the assumption that hospitals of specific types in the database resemble hospitals nationwide with these same characteristics. For each type of hospital (defined by size, region, teaching status, and ownership), weights are calculated as the inverse of the fraction of national admissions for this subgroup represented in the database. These aggregate national estimates are made by using data from the American Hospital Association. The statistical weight assigned to each type of hospital by quarter allows derivation of national projections (see reference 10 for additional details). Although this adjusted projection strategy is relatively rudimentary, it enables national projections that account for some, but not all, selection biases in the Premier Perspectives database sample. The statistical weights vary from around 10 per case documented by the database in 2000 to around 5.5 in 2008 as a function of the increasing number of hospitals included in the database over time. For our sample of 12 644 hospitalizations, we projected 73 747 (95% CI, 51 247 to 96 245) cases of rFVIIa use nationwide during the study period.
Statistical Analysis
Our analyses identified annual trends in national inhospital rFVIIa use. To characterize patterns of use by indication, we produced a crosstabulation of indication category by year. We performed similar analyses for patient age, discharge disposition, and hospital characteristics. The unit of analysis was any "case" of rFVIIa use-any hospitalization during which rFVIIa was administered 1 or more times. We chose this case-based unit of analysis because it captures the medical decision-making component of care about whether to use or not use rFVIIa for a given patient. Alternative methods of analysis by dosing were considered (for example, volume of rFVIIa dispensed by the pharmacy) but were determined to have substantial disadvantages: possible discrepancies between dispensed rFVIIa and the amount actually administered, lack of consistent hospital coding of rFVIIa dispensing, and outlier cases. Anal-
Context
Although recombinant factor VIIa (rFVIIa) is approved only for treatment of bleeding in patients with hemophilia, physicians use it to prevent or treat bleeding in other situations.
Contribution
Investigators examined 12 644 discharge records of patients who received rFVIIa at U.S. hospitals from 2000 to 2008. During that time, off-label use of rFVIIa increased more than 140-fold, whereas use for hemophilia increased less than 4-fold. In 2008, 97% of the in-hospital use of rFVIIa was for off-label indications, including cardiovascular surgery, trauma, and intracranial hemorrhage.
Implication
There is troubling, widespread off-label use of rFVIIa in U.S. hospitals.
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Off-Label Use of Recombinant Factor VIIa yses were done by using SAS software, version 9.2 (SAS Institute, Cary, North Carolina). We calculated 95% CIs for counts of hospital cases and proportions by using the SURVEYMEANS procedure in SAS, which accounted for selection of a national sample of hospitals.
Role of the Funding Source
The Agency for Healthcare Research and Quality funded the study. The funding source had no role in the study design, data collection and interpretation, writing of the report, or decision to submit the manuscript for publication. Cases signify the number of hospitalizations during which recombinant factor VIIa was used. All cases for each year are depicted. The width of each segment represents the number of cases for each category, as indicated by differential shading. Hemophilia includes hemophilia A and B, and trauma includes body and brain trauma. ICH ϭ intracranial hemorrhage. Figure) . Intracranial hemorrhage accounts for 11% (CI, 6.9% to 14%) of cases overall and 11% (CI, 7.7% to 14%) of cases in 2008.
RESULTS
Liver Disease
A range of indications related to liver disease account for 6% (CI, 2.5% to 9.3%) of all uses, including liver biopsy (1.2%), variceal bleeding (1.2%), liver transplantation (0.2%), and other liver indications (3.3%).
Other Conditions
Gastrointestinal bleeding other than that associated with esophageal varices or liver disease accounted for 5.3% (CI, 3.2% to 7.4%) of cases overall. Management of aortic aneurysm, in the presence and absence of surgical intervention, represented 1.7% of use overall and in 2008. Other conditions contributed minimally to rFVIIa use, including pulmonary indications, particularly biopsy and lung transplantation (1.5% overall); cancer-related conditions, particularly leukemia (1.5%); neonatal indications (1%); obstetric conditions, particularly postpartum hemorrhage (0.9%); and several surgical procedures, none of which was individually prominent (5.3% overall and 2.2% in 2008). Various secondary clotting disorders were associated with rFVIIa use (5.1% overall and 4.2% in 2008), including secondary thrombocytopenia and complications of warfarin anticoagulation.
Age Distribution
Consistent with the growth of off-label indications, the mean age of patients has increased from 3 years (CI, 
Discharge Disposition
Overall in-hospital mortality among patients who received rFVIIa was 27% (CI, 19% to 34%). Only 43% (CI, 26% to 59%) of patients were discharged directly home ( Table 2 ). Most of the remaining patients were transferred to other facilities (for example, nursing homes and rehabilitation hospitals). Mortality increased from 5% (CI, 0% to 35%) in 2000 to a peak of 31% (CI, 24% to 37%) in 2004 but declined slightly to 27% (CI, 25% to 30%) in 2008. Mortality among patients with hemophilia A and B was 4% (CI, 1.8% to 5.8%). The highest mortality rates were associated with aortic aneurysm (54% [CI, 43% to 65%]), neonatal indications (47% [CI, 35% to 59%]), and nonvariceal complications of liver disease (40% [CI, 32% to 48%]). Regarding the most common indications, mortality was 34% (CI, 31% to 38%) for spontaneous ICH, 33% (CI, 20% to 47%) for brain and body trauma, and 23% (CI, 21% to 26%) for adult cardiovascular surgery.
Hospital Characteristics
Use of rFVIIa was reported in 235 of the 615 hospitals (38%) represented in the Premier Perspectives database. Most rFVIIa use occurred in nonacademic hospitals (68% [CI, 39% to 97%]), a pattern that was consistent for most of the indications we studied (Figure 2) . Over time, the proportion of rFVIIa use in nonacademic hospitals grew from 11% (CI, 0% to 43%) in 2000 to a peak of 73% (CI, 31% to 71%) in 2005, followed by 67% (CI, 57% to 77%) in 2008. Off-label use of rFVIIa was lower at academic hospitals (92% [CI, 88% to 96%]) than at nonacademic hospitals (97% [CI, 96% to 98%]).
DISCUSSION
The potential for rFVIIa to be used as an emergency hemostatic agent outside the setting of hemophilia was recognized soon after its clinical introduction (11, 12) . Although this agent is currently approved by the FDA for certain uncommon conditions, its in-hospital use for these is now far exceeded by its use for off-label indications. By using a representative database of individual hospitalizations across the United States, we found that 96% of all in-hospital cases of rFVIIa use from 2000 to 2008 and 97% of cases in the year 2008 were off-label. These findings are consistent with past reports (13-21) (Appendix Table 2 , available at www.annals.org).
Adult cardiovascular surgery is the most rapidly emerging indication for rFVIIa use. In 2008, more than 1 in 4 patients who received rFVIIa were treated in the context of cardiovascular surgery. There is limited evidence to support this use. Diprose and colleagues (22) reported a randomized, controlled trial (RCT) with 20 patients (9 received rFVIIa) in which a single dose of rFVIIa was used prophylactically at the termination of cardiopulmonary bypass in noncoronary cardiovascular surgery. Although the need for allogeneic blood transfusion was significantly reduced after the administration of rFVIIa, there was no effect on patient survival. More recently, Gill and colleagues (23) reported a placebo-controlled RCT in which patients with bleeding episodes after cardiovascular surgery were randomly assigned to receive a single dose of rFVIIa at 40 mcg/kg (n ϭ 35) or 80 mcg/kg (n ϭ 69) versus placebo (n ϭ 68). Significant decreases in the need for reoperation and allogeneic blood transfusions were seen in the groups that received rFVIIa, but there were no differences in mortality. Furthermore, there were increases in thromboembolic adverse events, particularly stroke, in the rFVIIa groups, although they did not reach statistical significance.
Body trauma accounted for 18% of rFVIIa use in 2008 and was addressed by 2 simultaneously reported RCTs. Although these trials demonstrated a significant decrease in transfusion requirements and possible decrease in the acute respiratory distress syndrome, they also censored patients who died in the first 48 hours of rFVIIa adminis- GI ϭ gastrointestinal; rFVIIa ϭ recombinant factor VIIa.
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tration and yet demonstrated no mortality benefit (24 (Figure 2) . This suggests wide adoption of rFVIIa as a therapy despite concerns about its efficacy and safety.
We also conducted a comparative effectiveness review of in-hospital, off-label use of rFVIIa for 5 indications that demonstrated no evidence of mortality reduction but an increased risk for arterial thromboembolic events in cardiovascular surgery and nontraumatic ICH (27) . Levi and coworkers (28) similarly confirmed an increase in arterial thrombotic adverse events among all published RCTs investigating off-label use of rFVIIa. Previous analyses of voluntary reports to the FDA Adverse Event Reporting System identified deep venous thrombosis, ischemic cerebrovascular accident, and myocardial infarction as the most common adverse events associated with rFVIIa use (18, 19) . As noted by Aledort (29) , rare adverse events may not be clearly associated with an intervention on the basis of an individual trial; however, meta-analysis of several trials may provide insight into the risk for rare events, such as the thromboembolic adverse events that seem to be associated with off-label rFVIIa use. In our study, we were unable to estimate the incidence of patient harm associated with rFVIIa use because of insufficient information in the Premier Perspectives database on the temporal relationship between thromboembolic events and the use of rFVIIa.
An indirect measure of the efficacy of rFVIIa in the care of patients who receive it is survival to discharge. In the nationwide sample of hospitals that we analyzed, inhospital mortality for patients who received rFVIIa was high: 27% overall and as high as 40% to 50% for several indications ( Table 2) . In-hospital mortality has been noted to be higher in retrospective studies of rFVIIa use outside of clinical trials than that seen in carefully selected clinical trial populations (7, 10, 13, 27, 30, 31) .
Our study has several limitations. The Premier Perspectives database gathers data from a voluntary alliance of nonfederal hospitals and thus is not a random selection of health care facilities nationwide. Our analysis of indications associated with use of rFVIIa was confined to the primary and secondary diagnoses (as listed by ICD-9 code) reported for each hospitalization. We cannot validate these diagnoses or identify diagnostic codes that may have been omitted. In addition, the indication hierarchy we used to categorize rFVIIa use may not have captured the nuances of each individual case. For instance, we are unable to determine at what point in a disease process rFVIIa was used (for example, as prophylaxis, as treatment, or for endstage catastrophic bleeding episodes). We also did not have access to data on patients with similar clinical scenarios in which rFVIIa was not used.
Although utilization of medications will change over time as additional hypotheses about patient therapeutics are examined, the key question is at what point has a new indication attained a sufficient evidence base to justify greatly expanded use. Given the absence of supporting data and the suggestion of patient harm, our analysis has identified probable nationwide overuse of rFVIIa outside the conditions approved by the FDA. We hope that this and similar analyses of real-world use of medications will provide guidance for the design of clinical trials and evidence reviews that adequately address the efficacy and associated harms of individual agents in the contexts in which they are most commonly used. If concerning patterns of offlabel use exist for other medications, these analyses may also help highlight areas for improvement in systems responsible for drug approval and subsequent surveillance.
